Clinical Trial Update: A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study updating results for TVP-1012 at 0.5 mg and 1 mg in Parkinson's Disease patients treated with levodopa; trial completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• TVP-1012

Snippet

Sponsor: Takeda | Conditions: Parkinson's Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-02-28